ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing

Key Takeaways

• ROIS secures FDA approval alongside EMA, PMDA, KFDA, ANVISA, and MHRA regulatory clearances for US market entry
• Company offers comprehensive CDMO services for injectable formats including syringes, cartridges, and vials
• US expansion positions ROIS as global contract manufacturing partner for pharmaceutical companies seeking multi-regional regulatory compliance

---

ROIS has officially established its presence in the United States pharmaceutical market, positioning itself as a global contract development and manufacturing organization (CDMO) with comprehensive regulatory approvals from major international health authorities.

The company’s US expansion comes with critical regulatory endorsements from the FDA, European Medicines Agency (EMA), Japan’s PMDA, South Korea’s KFDA, Brazil’s ANVISA, and the UK’s MHRA. This multi-regional approval portfolio enables ROIS to serve pharmaceutical clients across major global markets with standardized manufacturing processes.

Comprehensive Injectable Manufacturing Services

ROIS specializes in end-to-end support for injectable drug products, covering three primary delivery formats: pre-filled syringes, cartridges, and vials. This comprehensive approach addresses the growing demand for injectable therapeutics, particularly in biologics and specialty pharmaceuticals where precise manufacturing standards are essential.

The company’s manufacturing capabilities span the entire development lifecycle, from early-stage formulation through commercial production. This integrated service model allows pharmaceutical companies to streamline their supply chains while maintaining compliance across multiple regulatory jurisdictions.

Strategic Market Positioning

The US market entry represents a significant milestone for ROIS, as the United States remains the world’s largest pharmaceutical market. By establishing operations in the US while maintaining its existing international approvals, ROIS can offer clients a truly global manufacturing network.

This expansion addresses a critical need in the pharmaceutical industry for CDMOs capable of managing complex regulatory requirements across multiple regions. Companies developing injectable products often face challenges coordinating manufacturing standards between different regulatory environments, making ROIS’s multi-approval status particularly valuable.

The timing of this expansion aligns with increased demand for contract manufacturing services, as pharmaceutical companies increasingly outsource production to focus on research and development activities. ROIS’s comprehensive regulatory portfolio positions the company to capture market share in this growing segment.

---

Frequently Asked Questions

What types of injectable products can ROIS manufacture?

ROIS provides end-to-end manufacturing support for injectable drugs in three formats: pre-filled syringes, cartridges, and vials, covering the full spectrum of injectable delivery systems.

Which regulatory approvals does ROIS hold for its US operations?

ROIS has secured approvals from six major regulatory bodies: FDA (US), EMA (Europe), PMDA (Japan), KFDA (South Korea), ANVISA (Brazil), and MHRA (UK).

How does ROIS’s global approval status benefit pharmaceutical clients?

The multi-regional regulatory approvals allow pharmaceutical companies to use ROIS for manufacturing products destined for multiple global markets while maintaining consistent quality standards and regulatory compliance.